Compare iShares Global Clean Energy ETF (ICLN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares Global Clean Energy ETF trades at $17.28 (market cap $2.30B), while Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 33.2× iShares Global Clean Energy ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while iShares Global Clean Energy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 87 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| ICLN | REGN | |
|---|---|---|
Market Cap | $2.30B | $76.40B |
Volume | 3,661,617 | 626,381 |
52-Week High | $23.75 | $852.03 |
52-Week Low | $15.78 | $557.73 |
Typical Hold Time | 87 Days | 107 Days |
Sector | — | Health |
Enterprise Value | — | $71.12B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $17.31, down 1.31% with a bearish technical signal from moving averages. The ETF faces volatility with clean energy exposure showing deeper drawdowns compared to traditional energy peers. Recent news highlights competitive pressure from fossil fuel ETFs delivering stronger returns and lower fees, though geopolitical tensions are accelerating global renewable energy adoption.
The outlook remains challenged by high expense ratios and sector volatility, but long-term growth potential exists from global energy transition trends. Key risks include competitive pressure from traditional energy and execution challenges in renewable adoption timelines.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
